The pharmaceutical company Novartis has presented long-term data on the drug Cosentyx (secukinumab) in use against the skin disease hidradenitis suppurativa (HS).
ttn-28
Exclusive Student Offer
Prime for Young Adults
Get a 6-month trial with premium college perks & fast delivery.
Listen Anywhere
Audible Standard Trial
Get 30 days of audiobooks free. Cancel anytime, keep your books.
As an Amazon Associate, we earn from qualifying purchases.